Acción GFOR.U GRAF ACQUISITION CORP. IV
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Graf Acquisition Corp. IV Nyse

Acciones

GFOR.U

US3842722098

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Graf Acquisition IV : Unaudited Condensed Consolidated Financial Statements - Form 8-K
NKGen Biotech, Inc. Announces Closing of Business Combination
NKGen Biotech, Inc. completed the acquisition of Graf Acquisition Corp. IV from Graf Acquisition Partners IV LLC, Adage Capital Management, L.P. and others in a reverse merger transaction.
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Graf Acquisition Corp. IV Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company
Graf Acquisition IV : NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference - Form 8-K
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
GRAF ACQUISITION CORP. IV : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
Graf Acquisition Corp. IV Reports Earnings Results for the First Quarter Ended March 31, 2023
Graf Acquisition IV : NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV - Form 8-K
GRAF ACQUISITION CORP. IV : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Graf Acquisition Corp. IV Announces Resignation of Sterling Cross as Chief Financial Officer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción NKGN
  4. Acción GFOR.U
  5. Noticias Graf Acquisition Corp. IV
  6. Otros idiomas